Clinical Nutrition Center

5 Common GLP-1 Mistakes That Undermine Your Results

2026-06-08T22:28:25Z

Eight-five percent. That’s how many people stop taking their GLP-1 medication within two years. Not because the drugs stopped working. Not because they got lazy. Because the approach was wrong from the start. GLP-1 medications—Ozempic, Wegovy, Zepbound, Foundayo and their cousins—are genuinely powerful tools. They also require a certain structure to succeed. Without that structure, […]

The post 5 Common GLP-1 Mistakes That Undermine Your Results first appeared on Clinical Nutrition Center.

GLP-1 Medications and Cancer Risk: What a New Study Shows

2026-06-02T23:11:23Z

GLP-1 Medications and Cancer Risk: What a New Study Shows Published May 26, 2026 | Dr. Ethan Lazarus, MD A new study adds to a growing body of evidence that GLP-1 receptor agonists may do more than lower blood sugar and reduce body weight — they may also lower cancer risk. Presented at Digestive Disease […]

The post GLP-1 Medications and Cancer Risk: What a New Study Shows first appeared on Clinical Nutrition Center.

Protein on GLP-1s: How to Eat to Preserve Muscle and Keep Losing Fat | Denver

2026-06-02T16:09:41Z

A patient came in last month frustrated. She’d been on a GLP-1 medication for four months, had lost 18 pounds — and yet her body composition told a different story. She’d dropped muscle, not just fat. When I asked her what she’d been eating, she shrugged. “I just don’t have much of an appetite anymore. […]

The post Protein on GLP-1s: How to Eat to Preserve Muscle and Keep Losing Fat | Denver first appeared on Clinical Nutrition Center.

Why Your GLP-1 Might Not Be Working — and What a Medical Team Can Actually Do About It

2026-05-01T21:54:07Z

For years, the standard answer was: eat less, move more. If that didn’t work, you didn’t try hard enough. We know better now. GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) work — in clinical trials, they work remarkably well. The problem isn’t the drugs. The problem is what happens in the real […]

The post Why Your GLP-1 Might Not Be Working — and What a Medical Team Can Actually Do About It first appeared on Clinical Nutrition Center.

5 GLP-1 Mistakes Patients Make (And How to Avoid Them)

2026-04-27T14:59:18Z

If you’re on a GLP-1 medication—or thinking about starting one—you owe it to yourself to get this right. These drugs work. But I see the same mistakes over and over in my Colorado obesity practice, and they cost people results, money, and sometimes their health. Here are the five most common. Mistake #1: Using medication […]

The post 5 GLP-1 Mistakes Patients Make (And How to Avoid Them) first appeared on Clinical Nutrition Center.

Survodutide Phase 3: 16.6% Weight Loss in Adults with Obesity

2026-05-25T23:10:49Z

New Phase 3 Data: Survodutide Delivers 16.6% Weight Loss — Dual GLP-1/Glucagon Agonist Shows Metabolic Benefits Beyond the Scale The SYNCHRONIZE-1 Phase 3 trial results are in — and they’re worth your attention. Survodutide (BI 456906), Boehringer Ingelheim’s novel dual glucagon/GLP-1 receptor agonist, achieved 16.6% average weight loss at 76 weeks in adults with obesity, […]

The post Survodutide Phase 3: 16.6% Weight Loss in Adults with Obesity first appeared on Clinical Nutrition Center.

Amazon’s GLP-1 Program: Is Convenience Enough?

2026-04-27T17:27:44Z

Amazon just entered the weight loss drug business. And if you’ve been watching the GLP-1 space, you probably saw it coming. On April 21, 2026, Amazon launched a GLP-1 Management Program through Amazon One Medical — combining virtual visits, prescription fulfillment, and pharmacy delivery under one roof. The marketing is polished. The prices are competitive. […]

The post Amazon’s GLP-1 Program: Is Convenience Enough? first appeared on Clinical Nutrition Center.

GLP-1 Drugs Help Your Liver Before Weight Loss: Denver Research

2026-04-27T16:55:12Z

For years, the prevailing assumption was simple: GLP-1 drugs help the liver because they help you lose weight. Cut calories, shed pounds, your liver gets less fat, inflammation calms down. Thglp-1hanism seemed obvious. New research from Sinai Health in Toronto just made that assumption obsolete. What the Study Found Researchers discovered that semaglutide acts directly […]

The post GLP-1 Drugs Help Your Liver Before Weight Loss: Denver Research first appeared on Clinical Nutrition Center.

Foundayo vs. Oral Wegovy vs. Zepbound: Making Sense of the GLP-1 Options

2026-04-27T16:55:10Z

Not all GLP-1s are the same. And for the first time in this drug class, you actually have real choices. With orforglipron (Foundayo) now FDA-approved and oral Wegovy (25 mg semaglutide) newly available, patients and doctors face a genuinely useorforglipron: which oral option is right for me? Let’s break it down without the marketing noise. […]

The post Foundayo vs. Oral Wegovy vs. Zepbound: Making Sense of the GLP-1 Options first appeared on Clinical Nutrition Center.

Retatrutide: What Lilly’s Triple-Agonist Drug Means for Weight Loss Treatment

2026-05-01T12:39:51Z

Let me start with a number that should get your attention: 28.7%. That’s how much body weight participants lost in the latest Phase 3 trial of retatrutide, Eli Lilly’s investigational triple-agonist obesity medication. At 68 weeks, the average weight loss was 71.2 pounds. More than half of participants taking the highest dose lost at least […]

The post Retatrutide: What Lilly’s Triple-Agonist Drug Means for Weight Loss Treatment first appeared on Clinical Nutrition Center.